Innovative Biotech Company Announces Agreement To Perform CBD Pill Clinical Study

Dr. Jim Woody, CEO of 180 Life Sciences Corp. ATNF, was recently a guest on Benzinga’s All-Access.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain. The company’s primary platform is a novel program to treat fibrosis and inflammation using anti-TNF, with its lead program in phase 2b/3 clinical trial.

180 has recently entered into an agreement to conduct clinical trials of a formulation of CBD that can be taken in pill form. CBD has been approved by the FDA for several indications but current administration as an oral oil is difficult and inconvenient.

Learn more here:

Featured photo by danilo.alvesd on Unsplash.

This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechPenny StocksInterviewGeneral180 Life Sciences CorpBenzinga All Access
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!